Archeon Medical, a company focused on enhancing manual ventilation during critical care, has closed a $9.0M Series A funding round. The capital infusion will support its mission to "fix the broken link in the chain of survival by putting the P back in CPR," providing emergency responders, hospitals, and military organizations with real-time feedback devices.
The round saw participation from investors including Newfund, Eiffel Investment Group, UI Investissement, Majycc Innovation Santé - UI Investissement, and Karot Capital. Archeon Medical's key offerings, EOlife and EOlife X, are designed to ensure high-quality manual ventilation by measuring the volume of gas reaching a patient's lungs, with EOlife already CE-marked and FDA-cleared.
